Solid Biosciences Inc., a life science company based in Charlestown, Massachusetts, is making strides in the development of therapies for neuromuscular and cardiac diseases in the United States. At the forefront of their agenda is the development of SGT-003, their lead product candidate, which is a next-generation gene transfer candidate designed to treat Duchenne muscular dystrophy (Duchenne). The company is also actively working on AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia, AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy, and other drugs for the treatment of undisclosed cardiac diseases. In addition, the company is focusing on developing platform technologies, particularly on dual gene expression, a technology that allows for the packaging of multiple transgenes into one vector, as well as novel capsids. Solid Biosciences Inc. has a collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne.
Solid Biosciences's ticker is SLDB
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Solid Biosciences
It is solidbio.com
Solid Biosciences is in the Healthcare sector
Solid Biosciences is in the Biotechnology industry
The following five companies are Solid Biosciences's industry peers: